MedTrace Logo

Quadratus Lumborum Block for Post-Cesarean Analgesia

NCT02339766 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-10-22

No results posted yet for this study

Summary

Most women having planned cesarean section receive spinal anesthetic for the procedure.

Typically, spinal opioids are administered during the same time as a component of multimodal analgesia to provide pain relief in the 16-24 hr period postoperatively. However, spinal opioids are frequently associated with adverse effects such as nausea, pruritus, sedation and occasionally respiratory depression.

The quadratus lumborum (QL) block is a regional analgesic technique which blocks T5-L1 nerve branches and has an evolving role in postoperative analgesia for lower abdominal surgeries and is a potential alternative to spinal opioids. There is some evidence that it may provide visceral along with somatic pain relief. It is a simple and safe technique that has been studied in lower abdominal surgeries, but has not been studied for pain relief after cesarean section.

If found effective, it will have the advantage of a reduction in opioid associated adverse effects while providing similar quality of analgesia. This block has evolved from the previously known transversus abdominis plane block.

We propose to undertake a study that will compare the relative efficacy of QL block with local anesthetic to spinal morphine. We will also study if it provides any incremental benefit when administered in addition to spinal morphine.

Conditions

  • Postoperative Pain

Interventions

PROCEDURE

Quadratus Lumborum Block

Quadratus Lumborum Block with Ropivacaine 0.5% will be done.

PROCEDURE

Sham Block

Sham block of Quadratus Lumborum will be done with Saline.

DRUG

Intrathecal Morphine

Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.

DRUG

Intrathecal Saline

Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Shalini Dhir, MD, FRCPC · University of Western Ontario, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2017-02-05
Completion
2017-02-05

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02339766 on ClinicalTrials.gov